Another Step Closer To Universal Allogeneic Cells
Anti-aging focused life sciences companies Juvenescence and AgeX have published an encouraging progress report in Regenerative Medicine regarding the development of hypoimmunogenic/universal allogeneic cells. Autologous cell therapy uses a patient’s own cells, while allogeneic cell therapy uses donor cells. Using an allogeneic approach is superior in quality, scalability, manufacturing cost, commercialisation, and much more. However, …